HC Wainwright Reaffirms “Buy” Rating for IceCure Medical (NASDAQ:ICCM)

HC Wainwright reissued their buy rating on shares of IceCure Medical (NASDAQ:ICCM) in a research report report published on Tuesday morning, Benzinga reports. HC Wainwright currently has a $3.00 target price on the stock.

Separately, Alliance Global Partners upped their price objective on shares of IceCure Medical from $1.90 to $2.90 and gave the stock a buy rating in a research report on Wednesday, March 20th.

IceCure Medical Price Performance

IceCure Medical stock opened at $1.30 on Tuesday. The stock has a fifty day moving average of $1.28 and a 200-day moving average of $1.11. The stock has a market capitalization of $59.31 million, a P/E ratio of -3.94 and a beta of 0.73. The company has a debt-to-equity ratio of 0.03, a quick ratio of 3.08 and a current ratio of 3.66. IceCure Medical has a 52 week low of $0.52 and a 52 week high of $1.57.

IceCure Medical (NASDAQ:ICCM) last issued its earnings results on Wednesday, April 3rd. The company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.08) by $0.01. The firm had revenue of $1.26 million during the quarter. IceCure Medical had a negative return on equity of 86.96% and a negative net margin of 453.76%. During the same period in the previous year, the firm posted ($0.11) EPS. On average, sell-side analysts expect that IceCure Medical will post -0.28 earnings per share for the current fiscal year.

Institutional Investors Weigh In On IceCure Medical

Several hedge funds have recently modified their holdings of ICCM. Boothbay Fund Management LLC increased its holdings in IceCure Medical by 100.0% in the 4th quarter. Boothbay Fund Management LLC now owns 40,000 shares of the company’s stock worth $62,000 after purchasing an additional 20,000 shares in the last quarter. Bank of America Corp DE grew its holdings in shares of IceCure Medical by 57.2% during the fourth quarter. Bank of America Corp DE now owns 55,388 shares of the company’s stock worth $86,000 after purchasing an additional 20,159 shares during the last quarter. UBS Group AG grew its holdings in shares of IceCure Medical by 1,302.3% during the fourth quarter. UBS Group AG now owns 28,986 shares of the company’s stock worth $45,000 after purchasing an additional 26,919 shares during the last quarter. Finally, JPMorgan Chase & Co. acquired a new position in shares of IceCure Medical in the second quarter valued at approximately $78,000. Institutional investors and hedge funds own 0.62% of the company’s stock.

About IceCure Medical

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and commercialization of medical devices for cryoablation (freezing) of tumors in the human body. It offers ProSense system, a single probe system for the treatment of breast tumors; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.